22 Sep 2025 | 5 Mins Read
Ajanta Pharma: Buy at Rs 3200, says Prabhudas Lilladher
Flipitmoney
Prabhudas Lilladher initiated coverage with a 'BUY' rating and Rs3,200 target price, a 25% upside from current levels. Ajanta Pharma's branded generics market segment contributed 74% to revenue in FY25 with a 12.5% CAGR from FY22-25. Estimating a 13% revenue CAGR and 17% EBITDA/CAGR over FY25-28E, it expects EPS growth to justify a 30x P/E valuation.